![Andrew Wingate](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Andrew Wingate
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Onebiopharma, Inc.
![]() Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA.
3
| Private Company | Medical/Nursing Services | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Andrew Wingate tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
JOHNSON & JOHNSON | Pharmaceuticals: Major | Founder | |
ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer | |
Pulmatrix Operating Co., Inc.
![]() Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member | |
KYTHERA BIOPHARMACEUTICALS INC | Pharmaceuticals: Major | Founder | |
LUNGLIFE AI, INC. | Medical/Nursing Services | Director/Board Member | |
Cytrellis Biosystems, Inc.
![]() Cytrellis Biosystems, Inc. Medical SpecialtiesHealth Technology Cytrellis Biosystems, Inc. designs and develops aesthetic devices. The company was founded by William Gerald Austen and Doug A. Levinson and is headquartered in Boston, MA. | Medical Specialties | Chairman | |
Oxeia Biopharmaceuticals, Inc.
![]() Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder Chief Executive Officer | |
Astra Merck, Inc.
![]() Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Purdue University | College/University | Doctorate Degree | |
University of California, Riverside | College/University | Undergraduate Degree | |
University of Connecticut | College/University | Undergraduate Degree | |
Percivia LLC
![]() Percivia LLC Miscellaneous Commercial ServicesCommercial Services Percivia LLC engages in the research and development of vaccine and recombinant protein products. The company was founded in 2006 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer | |
Peter F Drucker & Masatoshi Ito Graduate School of Management | College/University | Masters Business Admin | |
Nephrian, Inc. | Founder | ||
EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer President | |
Enterprise Therapeutics Ltd.
![]() Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Chairman | |
PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
Adrista, Inc. | Director/Board Member | ||
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Orna Therapeutics, Inc.
![]() Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chief Executive Officer | |
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. IV | Financial Conglomerates | Director/Board Member | |
ZURA BIO LIMITED | Biotechnology | Chairman | |
Renagade Therapeutics, Inc.
![]() Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Chief Executive Officer |
Statistiche
Distribuzione geografica
Stati Uniti | 26 |
Regno Unito | 3 |
Svizzera | 2 |
Settori
Health Technology | 19 |
Consumer Services | 5 |
Health Services | 2 |
Commercial Services | 2 |
Finance | 2 |
Posizioni
Director/Board Member | 19 |
Chief Executive Officer | 10 |
President | 5 |
Corporate Officer/Principal | 5 |
Chairman | 4 |
Contatti più connessi
Insiders | |
---|---|
Amit Munshi | 27 |
Michael Wyand | 6 |
Elon Boms | 1 |
- Borsa valori
- Insiders
- Andrew Wingate
- Connessioni Società